Search Results
Your search for ,now matches 6673 pages
Showing 2501 - 2550AML Pioneer and Giant, Clara D. Bloomfield, MD, FASCO, Dies at 77
Physicians and scientists interested in acute myeloid leukemia (AML) have lost one of the community’s shining lights with the death of Clara D. Bloomfield, MD, FASCO, on March 1, 2020, at age 77 years. Dr. Bloomfield is well known for her more than 50 years of groundbreaking research in blood...
I Wasn’t Prepared for the Emotional Turmoil of Breast Cancer
Nearly a decade ago, my mother tested positive for the BRCA1 mutation; soon after, my twin sister and I were tested for the inherited defective gene, and I learned I, too, have the BRCA1 mutation. My sister is not a carrier of the mutation. Although there is a long history of both breast and...
The Opioid Crisis as Told From the Streets to the Clinics and Its Unintended Consequences
The history of drug addictions and epidemics in the United States dates back to the Civil War, when morphine was introduced as a pain medication for wounded soldiers. Regular off-label use of morphine quickly spread from war hospitals to the general public. It is estimated that more than 400,000...
A Cello for Michayla
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Randall A. Oyer, MD, Named President of the Association of Community Cancer Centers
At the Association of Community Cancer Centers (ACCC) 46th Annual Meeting & Cancer Center Business Summit, held March 4–6 in Washington, DC, Randall A. Oyer, MD, was named ACCC President for 2020–2021. Dr. Oyer announced that the theme of his presidency will be “Community Oncology Can Close the ...
Cancer During Pregnancy: Whose Moral Compass to Follow?
As has often been written, “Cancer is the greatest equalizer.” It tends to strike its victims regardless of their financial status. In low- and middle-income countries, however, the impact of poverty on the treatment of cancer is strikingly conspicuous. It is the major catalyst for delay in seeking ...
Oncologists on the Front Lines of COVID‑19
Coronavirus disease 2019 (COVID-19) is dramatically affecting health-care systems. This is the first in a series of interviews The ASCO Post will conduct with oncologists, to learn what they and their cancer centers are doing to deal with the crisis. In this article, we talk with John Cole, MD, a...
Pembrolizumab in MSI-H and CPS ≥ 10 Advanced Gastric or Gastroesophageal Junction Cancer: Subanalysis of KEYNOTE-059, -061, and -062
The survival benefit of pembrolizumab in advanced gastric/gastroesophageal junction cancer with microsatellite instability–high (MSI-H) tumors or a combined positive score (CPS) ≥ 10 was established in post hoc subanalysis of three KEYNOTE trials. Findings were presented at the 2020...
Cisplatin/Gemcitabine Alone and With Veliparib in BRCA-Mutated Advanced Pancreatic Cancer
In patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, first-line therapy with cisplatin plus gemcitabine yielded high response rates and encouraging survival, according to Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, who presented the findings...
Mature Follow-up of BEACON CRC Study Reports Quality-of-Life Measures and Survival Outcomes
For patients with previously treated metastatic colorectal cancer harboring BRAF V600E mutations, the phase III BEACON CRC study showed the benefit for combining two or three targeted agents vs the standard of care.1 With further follow-up, the study has now also shown a benefit for the triplet and ...
Conference Highlights From the 2020 Gastrointestinal Cancers Symposium
This past January, the 2020 Gastrointestinal Cancers Symposium was held in San Francisco. More than 3,600 individuals attended and more than 900 abstracts and posters were presented. Among the highlights presented at the meeting and reported in the pages of The ASCO Post, several studies in...
A Case of Diffuse Large B-Cell Lymphoma
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 52-year-old man who found a neck mass himself. He went to his doctor and was prescribed antibiotics. When the antibiotics failed to impact the mass, a biopsy was performed and a diagnosis ...
A Case of Relapsed/Refractory Multiple Myeloma
Dr. Armitage presents a case and asks Dr. Holstein to comment about her approach to treatment. The patient is be a 59-year-old man who had presented with symptomatic myeloma with bone pain and he was feeling unwell. He had bone lesions on images. He was anemic. This all happened 2 years ago. He was ...
Trends in Deaths From Cutaneous Melanoma in the United States
Recent treatment advances in metastatic melanoma resulted in reductions in population-level mortality from the disease, according to a study published by Polsky et al in the American Journal of Public Health. Methods Researchers analyzed new cases and deaths from melanoma from nine U.S....
COVID-19 May Remain Stable for Hours to Days in Aerosols and on Surfaces
The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study published as a research letter in The New England Journal of Medicine. A team of researchers from the National Institutes of Health (NIH); the Centers ...
Continuous Coverage of COVID-19
The staff of The ASCO Post recognizes the steady flow of news on the novel coronavirus, or COVID-19. Here, we've compiled a list of links to articles and resources on the COVID-19 pandemic. If you have a report you'd like to share, please e-mail it to us at editor@ascopost.com. Direct From ASCO:...
Mitigating the Spread of COVID-19 and Its Impact on Cancer
On March 11, the World Health Organization (WHO) took the step it had been avoiding for weeks and declared that the spread of the coronavirus disease 2019 (COVID-19), and the virus that causes it, now identified as SARS-CoV-2, had reached global pandemic levels, the first pandemic sparked by a...
New ASCO Guideline Highlights the Management of Male Breast Cancer
THE ANNUAL INCIDENCE of male breast cancer in the United States is dwarfed by the rate among women. Yet, for the estimated 2,670 men who will be diagnosed with breast cancer this year, life-extending and life-enhancing treatments are crucial.1 To help reduce knowledge gaps and improve mortality and ...
Study Focuses on Role of Microbes in Pancreatic Cancer
Although bacteria are predominant in the gastrointestinal tract, they also reside on and in other parts of the body, including some unexpected places, such as malignant tumors. There are numerous reports of this phenomenon, but most have not identified a functional role for the microbes. In the...
HAPLO2019: Advances in Haploidentical Transplantation and Other Novel Cellular Therapies
Now in its seventh year, the Haploidentical Transplant Symposium (HAPLO) continues to explore advances in haploidentical and other novel cellular therapies. The most recent of these meetings—HAPLO2019—met in Orlando, Florida, 2 days before the start of the 2019 American Society of Hematology (ASH)...
Survival Benefits Achieved With Pembrolizumab in MSI-H and CPS ≥ 10 Gastric/Gastroesophageal Junction Cancer
Post hoc subanalyses of three KEYNOTE trials established the survival benefit of pembrolizumab in advanced gastric/gastroesophageal junction cancer with microsatellite instability–high (MSI-H) tumors or a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10 (ie, the number of...
QOPI Round 1 Now Open for Data Abstraction: Improve Quality Practice-Wide
ASCO’s Quality Oncology Practice Initiative (QOPI®) Round 1 of reporting is open for data abstraction. Round 1 will close on June 5, 2020, and final reports will be available approximately 4 weeks later. To get started, go to the registration portal at myqopi.asco.org/registration/login.aspx and...
Roles Are Reversed in ‘Personalized Medicine’ as Physicians Care for Parents With Cancer
As early-career oncologists, Rachna Shroff, MD, and Nina Shah, MD, offered patients a textbook bedside manner—personal interactions were limited, and emotions were rarely shared. “People talk about how, especially in oncology, the more you let [a patient] in, the more profoundly you feel losses,...
Therapy Is Keeping My Metastatic Breast Cancer Manageable
Despite being vigilant about adhering to my annual schedule of screening mammography, in 2002, I was diagnosed with stage III triple-negative breast cancer. The diagnosis scared me, and I wondered if I was going to die. Determined to do what I could to survive the cancer, I underwent aggressive...
Susan Band Horwitz, PhD, Named Recipient of 2020 Szent-Györgyi Prize
The National Foundation for Cancer Research (NFCR) recently announced that Susan Band Horwitz, PhD, has been selected to receive the 2020 Szent-Györgyi Prize for Progress in Cancer Research. Dr. Horwitz is being recognized for pioneering the understanding, at the molecular level, of the mechanisms...
Former ASCO President Sandra M. Swain, MD, FACP, FASCO, Shares Highlights of a Noted Career
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sandra M. Swain, MD, FACP, FASCO, Professor of Medicine and Associate Dean for Research Development at Georgetown University Medical Center, and Vice President of MedStar Genetic Medicine at Medstar...
Brief Highlights From the 2019 San Antonio Breast Cancer Symposium
In addition to our regular coverage of the 2019 San Antonio Breast Cancer Symposium, the following reports from the meeting include studies you may have missed. We hope you find them of interest. Ribociclib/Letrozole as Neoadjuvant Therapy As neoadjuvant therapy in women with high-risk hormone...
Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast...
Expert Point of View: James N. Gerson, MD
James N. Gerson, MD, Assistant Professor of Medicine at Perelman School of Medicine, University of Pennsylvania, Philadelphia, commented on the implications of the findings from CAPTIVATE. “Upfront therapy for chronic lymphocytic leukemia (CLL) is rapidly evolving. We now have three...
Treating Patients With Chronic Lymphocytic Leukemia in 2020
With the availability of a number of effective targeted agents for the treatment of chronic lymphocytic leukemia (CLL), the question arises whether chemotherapy still has a role in treating this malignancy. At the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, CLL...
Expert Point of View: Javier Pinilla-Ibarz, MD, PhD
Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center, Tampa, Florida, commented on this study: “ELEVATE TN compared front-line treatment with acalabrutinib alone or in combination with obinutuzumab vs obinutuzumab/chlorambucil and showed that a second-generation Bruton’s tyrosine kinase (BTK)...
ASCO and CAP Release Updated Guideline on Estrogen and Progesterone Testing in Breast Cancer
ASCO and the College of American Pathologists (CAP) have jointly published an update to a clinical practice guideline on estrogen receptor and progesterone receptor testing in breast cancer.1 The guideline for immunohistochemistry testing of estrogen receptor and progesterone receptors in patients...
Vitamin D Supplementation May Protect Against Checkpoint Inhibitor–Induced Colitis
Vitamin D supplementation prior to starting immune checkpoint inhibitor therapy may significantly reduce the odds of developing colitis, according to a study conducted at Harvard Medical School. Although this was a retrospective chart review, the association was relatively strong in the...
Former FDA Commissioner Scott Gottlieb, MD, Relays Opinions on Coronavirus
Scott Gottlieb, MD, former Commissioner of the U.S. Food and Drug Administration (FDA), had some advice for attendees of the 37th Annual Miami Breast Cancer Conference in his keynote address at the meeting. While his formal presentation pertained to innovations in oncology drug development and...
NSABP B-42 Trial 10-Year Update: Impact of Extended Letrozole on Disease-Free Survival
“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no significant improvement in overall survival with letrozole, but letrozole continued to provide a...
Chemotherapy, Trastuzumab, and Pertuzumab in Early HER2-Positive, Node-Positive Breast Cancer: Six-Year Follow-up of APHINITY Trial
Martine J. Piccart, MD, PhD, FASCO, reported that at 6-year follow-up of the APHINITY trial there was a modest, but not statistically significant, overall survival benefit for the addition of pertuzumab to chemotherapy plus trastuzumab vs chemotherapy/trastuzumab as adjuvant therapy in patients...
Phase III HER2CLIMB Trial Yields Positive Data in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis
The investigational oral agent tucatinib added to trastuzumab/capecitabine reduced the risk of death by one-third and reduced the risk of disease progression or death by one-half in patients with heavily pretreated metastatic HER2-positive breast cancer, including those with untreated or previously ...
Expert Point of View: Daniel V.T. Catenacci, MD
Daniel V.T. Catenacci, MD, Associate Professor of Medicine and Director of the Gastrointestinal Oncology Program at the University of Chicago, was the JAVELIN Gastric 100 study’s invited discussant. After offering an extensive background on the use of immunotherapy in gastric or gastroesophageal...
FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma
On March 2, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa) in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. ...
New Guideline Tackles Rapidly Evolving Imaging Strategies for Advanced Prostate Cancer
Advances in radiology and molecular imaging have the potential to significantly change how clinicians diagnose, stage, and monitor response to therapy in patients with prostate cancer. However, there are limited data comparing these next-generation imaging modalities to each other and to...
Plasma-Based Tumor Mutational Burden May Predict Response to Immunotherapy in Patients With Metastatic NSCLC
Patients with non–small cell lung cancer (NSCLC) with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to certain immunotherapy treatments than patients with a lower measure of mutations. A clinical trial showed that in cases where liquid...
FDA Pipeline: Priority Review in Lung Cancer, Breakthrough Therapy Designation in Head and Neck Cancer, and More
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to brigatinib for the treatment of ALK-positive lung cancer and Breakthrough Therapy designation to a potential first-in-class oral antagonist of inhibitors of apoptosis proteins for the treatment of head and neck...
Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients
As the number of solid organ transplants in the United States rises, cancer in this patient population is a growing concern. In fact, solid organ transplant recipients have an up to 50 times greater risk than the general population of developing skin cancers, and for kidney transplant recipients,...
QOPI Round 1 Now Open for Data Abstraction: Improve Quality Practice-Wide
ASCO’s Quality Oncology Practice Initiative (QOPI®) Round 1 of reporting is open for data abstraction. Round 1 will close on June 5, 2020, and final reports will be available approximately 4 weeks later. To get started, go to the registration portal at myqopi.asco.org/registration/login.aspx and...
Nebraska Oncology Society Supports Young Investigators, Expands Footprint Through Collaboration
The Nebraska Oncology Society (NOS) is now the fourth ASCO state affiliate committed to supporting Conquer Cancer, the ASCO Foundation, by funding a Young Investigator Award (YIA). “There’s a great need for oncologists in clinical practice, in general,” said NOS President Ralph Hauke, MD, FACP....
More Choices, More Flexibility With New Maintenance of Certification Pathway
Beginning this year, oncology specialists will have the opportunity to pursue a more flexible and less burdensome path to maintaining recertification. The American Board of Internal Medicine (ABIM)/ASCO Medical Oncology: Learning & Assessment (MOLA) is a lower-stakes Maintenance of...
Eileen Smith, MD, Named Chair, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope
Eileen Smith, MD, Medical Director of City of Hope’s Alpha Stem Cell Clinic, Associate Director of the Clinical Research Program, Clinical Professor in the Department of Hematology & Hematopoietic Cell Transplantation, has been appointed the new Chair of the Department of Hematology &...
Expert Point of View: Kevin Kalinsky, MD, MS
Commenting on SAFIR02-IMMUNO for The ASCO Post, Kevin Kalinsky, MD, MS, Associate Professor of Medicine at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, said the findings of the analysis were in accordance with other studies in metastatic breast cancer, but they came...
Expert Point of View: George A. Fisher, Jr, MD, PhD
George A. Fisher, Jr, MD, PhD, the Colleen Haas Chair in Medicine-Oncology at Stanford University School of Medicine, commented on the cell-free DNA methylation blood-based test from the Circulating Cell-Free Genome Atlas (CCGA) study. The findings presented by Dr. Wolpin, he said, “lead us to the ...
Value: Is the Benefit Worth the Cost?
AS A YOUNG CLINICIAN, I was interested in making a difference; it did not matter how much of a difference, as long as I could claim some patient benefit. And I really didn’t care what benefit: better survival, less local recurrence, shorter hospital stays, fewer narcotics—the specifics did not...
